Cargando…
Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications
Lysosomal storage diseases (LSDs) are a heterogeneous group of approximately 70 monogenic metabolic disorders whose diagnosis represents an arduous challenge for clinicians due to their variability in phenotype penetrance, clinical manifestations, and high allelic heterogeneity. In recent years, the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470217/ https://www.ncbi.nlm.nih.gov/pubmed/34576242 http://dx.doi.org/10.3390/ijms221810064 |
_version_ | 1784574142138286080 |
---|---|
author | La Cognata, Valentina Guarnaccia, Maria Morello, Giovanna Ruggieri, Martino Polizzi, Agata Cavallaro, Sebastiano |
author_facet | La Cognata, Valentina Guarnaccia, Maria Morello, Giovanna Ruggieri, Martino Polizzi, Agata Cavallaro, Sebastiano |
author_sort | La Cognata, Valentina |
collection | PubMed |
description | Lysosomal storage diseases (LSDs) are a heterogeneous group of approximately 70 monogenic metabolic disorders whose diagnosis represents an arduous challenge for clinicians due to their variability in phenotype penetrance, clinical manifestations, and high allelic heterogeneity. In recent years, the approval of disease-specific therapies and the rapid emergence of novel rapid diagnostic methods has opened, for a set of selected LSDs, the possibility for inclusion in extensive national newborn screening (NBS) programs. Herein, we evaluated the clinical utility and diagnostic validity of a targeted next-generation sequencing (tNGS) panel (called NBS_LSDs), designed ad hoc to scan the coding regions of six genes (GBA, GAA, SMPD1, IDUA1, GLA, GALC) relevant for a group of LSDs candidate for inclusion in national NBS programs (MPSI, Pompe, Fabry, Krabbe, Niemann Pick A-B and Gaucher diseases). A standard group of 15 samples with previously known genetic mutations was used to test and validate the entire flowchart. Analytical accuracy, sensitivity, and specificity, as well as turnaround time and costs, were assessed. Results showed that the Ion AmpliSeq and Ion Chef System-based high-throughput NBS_LSDs tNGS panel is a fast, accurate, and cost-effective process. The introduction of this technology into routine NBS procedures as a second-tier test along with primary biochemical assays will allow facilitating the identification and management of selected LSDs and reducing diagnostic delay. |
format | Online Article Text |
id | pubmed-8470217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84702172021-09-27 Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications La Cognata, Valentina Guarnaccia, Maria Morello, Giovanna Ruggieri, Martino Polizzi, Agata Cavallaro, Sebastiano Int J Mol Sci Article Lysosomal storage diseases (LSDs) are a heterogeneous group of approximately 70 monogenic metabolic disorders whose diagnosis represents an arduous challenge for clinicians due to their variability in phenotype penetrance, clinical manifestations, and high allelic heterogeneity. In recent years, the approval of disease-specific therapies and the rapid emergence of novel rapid diagnostic methods has opened, for a set of selected LSDs, the possibility for inclusion in extensive national newborn screening (NBS) programs. Herein, we evaluated the clinical utility and diagnostic validity of a targeted next-generation sequencing (tNGS) panel (called NBS_LSDs), designed ad hoc to scan the coding regions of six genes (GBA, GAA, SMPD1, IDUA1, GLA, GALC) relevant for a group of LSDs candidate for inclusion in national NBS programs (MPSI, Pompe, Fabry, Krabbe, Niemann Pick A-B and Gaucher diseases). A standard group of 15 samples with previously known genetic mutations was used to test and validate the entire flowchart. Analytical accuracy, sensitivity, and specificity, as well as turnaround time and costs, were assessed. Results showed that the Ion AmpliSeq and Ion Chef System-based high-throughput NBS_LSDs tNGS panel is a fast, accurate, and cost-effective process. The introduction of this technology into routine NBS procedures as a second-tier test along with primary biochemical assays will allow facilitating the identification and management of selected LSDs and reducing diagnostic delay. MDPI 2021-09-17 /pmc/articles/PMC8470217/ /pubmed/34576242 http://dx.doi.org/10.3390/ijms221810064 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article La Cognata, Valentina Guarnaccia, Maria Morello, Giovanna Ruggieri, Martino Polizzi, Agata Cavallaro, Sebastiano Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications |
title | Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications |
title_full | Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications |
title_fullStr | Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications |
title_full_unstemmed | Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications |
title_short | Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications |
title_sort | design and validation of a custom ngs panel targeting a set of lysosomal storage diseases candidate for nbs applications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470217/ https://www.ncbi.nlm.nih.gov/pubmed/34576242 http://dx.doi.org/10.3390/ijms221810064 |
work_keys_str_mv | AT lacognatavalentina designandvalidationofacustomngspaneltargetingasetoflysosomalstoragediseasescandidatefornbsapplications AT guarnacciamaria designandvalidationofacustomngspaneltargetingasetoflysosomalstoragediseasescandidatefornbsapplications AT morellogiovanna designandvalidationofacustomngspaneltargetingasetoflysosomalstoragediseasescandidatefornbsapplications AT ruggierimartino designandvalidationofacustomngspaneltargetingasetoflysosomalstoragediseasescandidatefornbsapplications AT polizziagata designandvalidationofacustomngspaneltargetingasetoflysosomalstoragediseasescandidatefornbsapplications AT cavallarosebastiano designandvalidationofacustomngspaneltargetingasetoflysosomalstoragediseasescandidatefornbsapplications |